Protium Science - CDMO is a South Korean company that specializes in the development of cell lines for biopharmaceutical production and the manufacturing of raw materials and finished pharmaceutical products in the entire CMC field. The company offers comprehensive and partial development, analysis, or experimental outsourcing according to customer needs. Additionally, it also provides optimal results tailored to the customer's goals, including the preparation of regulatory documents in the CMC part for clinical trial applications, ultimately aiming to grow together with the customer and the product.
Founded in 2021, Protium Science operates in the Analytics and Biotechnology industries with its headquarters located in South Korea. The company recently secured a KRW2.00B Corporate Round investment on April 4, 2024, with the investment coming from CJ헬스케어 (CJ HealthCare Corp.).